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Cell cycle status in neurodegeneration <p>Profiling of gene expression changes in mice harbouring the neurodegenerative Wlds mutation shows a strong correlation between  changes in cell cycle pathways and altered vulnerability of terminally differentiated neurons.</p>
Abstract
Background:  Altered neuronal vulnerability underlies many diseases of the human nervous
system, resulting in degeneration and loss of neurons. The neuroprotective slow Wallerian
degeneration (Wlds) mutation delays degeneration in axonal and synaptic compartments of neurons
following a wide range of traumatic and disease-inducing stimuli, providing a powerful experimental
tool with which to investigate modulation of neuronal vulnerability. Although the mechanisms
through which Wlds confers neuroprotection remain unclear, a diverse range of downstream
modifications, incorporating several genes/pathways, have been implicated. These include the
following: elevated nicotinamide adenine dinucleotide (NAD) levels associated with nicotinamide
mononucleotide adenylyltransferase 1 (Nmnat1; a part of the chimeric Wlds gene); altered mRNA
expression levels of genes such as pituitary tumor transforming gene 1 (Pttg1); changes in the
location/activity of the ubiquitin-proteasome machinery via binding to valosin-containing protein
(VCP/p97); and modified synaptic expression of proteins such as ubiquitin-activating enzyme E1
(Ube1).
Results: Wlds expression in mouse cerebellum and HEK293 cells induced robust increases in a
broad spectrum of cell cycle-related genes. Both NAD-dependent and Pttg1-dependent pathways
were responsible for mediating different subsets of these alterations, also incorporating changes in
VCP/p97 localization and Ube1 expression. Cell proliferation rates were not modified by Wlds,
suggesting that later mitotic phases of the cell cycle remained unaltered. We also demonstrate that
Wlds concurrently altered endogenous cell stress pathways.
Conclusion: We report a novel cellular phenotype in cells with altered neuronal vulnerability. We
show that previous reports of diverse changes occurring downstream from Wlds expression
converge upon modifications in cell cycle status. These data suggest a strong correlation between
modified cell cycle pathways and altered vulnerability of axonal and synaptic compartments in
postmitotic, terminally differentiated neurons.
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Background
Recent studies have highlighted the important role that vul-
nerability of nonsomatic neuronal compartments such as
axons and synapses plays in the instigation and progression
of neurodegenerative diseases, including Alzheimer's disease,
multiple sclerosis, prion disease, Huntington's disease, and
motor neuron diseases [1-4]. However, our understanding of
the independent mechanisms that are required to regulate
degenerative pathways in axons and synapses remains in its
i n f a n c y .  O n e  p o w e r f u l  e x p e r i m e n t a l  t o o l  t h a t  h a s  a l r e a d y
yielded novel insights into such pathways is the slow Walle-
rian degeneration (Wlds) mutation that selectively protects
axons and synapses in the central and peripheral nervous sys-
tems following a wide variety of traumatic and disease-
related, degeneration-inducing stimuli [5-12].
The Wlds mutation occurred spontaneously in a breeding col-
ony of C57Bl/6 mice, resulting in a tandem triplication of an
85 kilobase region on distal chromosome 4 [13]. The Wlds
gene encodes a fusion protein that comprises the full length of
nicotinamide mononucleotide adenylyltransferase 1
(Nmnat1; a nicotinamide adenine dinucleotide [NAD+] syn-
thesizing enzyme), coupled by a unique 18-amino-acid
sequence to the amino-terminal 70 amino acids of the ubiqui-
tination enzyme ubiquitination factor E4B (Ube4b) [14].
Transgenic expression of the Wlds gene is sufficient to confer
the full neuroprotective phenotype in several species, includ-
ing mice, rats, and Drosophila  [14-16]. Despite providing
substantial protection for axons and synapses, cell bodies are
not protected in Wlds mice [17-19].
The Wlds protein product appears to be localized exclusively
to neuronal nuclei, suggesting that it confers its neuroprotec-
tive effects indirectly via modification of endogenous cellular
pathways [14,20-22], but there remains considerable contro-
versy over which cellular pathways may need to be targeted to
confer Wlds-mediated neuroprotection. For example, several
studies have demonstrated that the NAD/Sirt1 pathway can
modulate axonal degeneration as a result of increased NAD
levels, driven by Nmnat1 in the chimeric Wlds gene [23-25].
However, NAD pathways alone are insufficient to confer the
full neuroprotective phenotype in vivo [26,27]. Other studies
have suggested that modifications of the ubiquitin-proteas-
ome system are required for neuroprotection, in part because
of the ability of Wlds to bind valosin-containing protein (VCP/
p97) [28,29]. Genomic and proteomic studies have identified
other downstream effects of Wlds expression in vivo and in
vitro. For example, array experiments have revealed modified
expression levels for a range of genes, including the robust
downregulation of mRNA encoding pituitary tumor trans-
forming gene 1 (Pttg1 [22,30]). Similarly, proteomic experi-
ments have demonstrated modifications in the levels of
mitochondrial and/or synaptic proteins such as ubiquitin-
activating enzyme E1 (Ube1) [31]. However, a unified hypo-
thesis that brings together these distinct observations is cur-
rently lacking.
We made the previously unrecognized observation that many
of these downstream changes also influence cell cycle. For
example, Pttg1 is an oncogene with a recently established role
in regulating the G1 to S phase transition of cell cycle [32].
Similarly, Ube1 is a protein with well established roles in cell
cycle [33-36], and VCP/p97 localization is intricately linked
to the cell cycle, with nuclear localization only occurring dur-
ing late G1 phase [37]. In addition, several studies have dem-
onstrated that NAD-dependent pathways play important
roles in regulating cell cycle [38-40]. Taken together with
numerous published studies reporting that cell cycle status
can play an important role in modulating neuronal vulnera-
bility and neurodegenerative pathways [41-49], these obser-
vations suggest that cell cycle modulation may provide a
unified, common pathway on which genetic and proteomic
changes downstream of Wlds  may act to confer
neuroprotection.
Here we show that Wlds expression in both mouse cerebellum
in vivo and in HEK293 cells in vitro leads to robust increases
in expression of a broad spectrum of cell cycle related genes,
indicative of an attempt to re-enter cell cycle. We also provide
evidence that these cell cycle changes involve all of the Wlds-
mediated pathways detailed above (Pttg1, Ube1, NAD, and
VCP), pushing postmitotic, terminally differentiated neurons
toward cell cycle re-entry without affecting later mitotic
phases. These data have identified a novel cellular phenotype
in  Wlds-expressing cells, unifying several diverse observa-
tions to reveal modifications in cell cycle status with concur-
rent alterations in cell stress. We propose that there exists a
strong correlation between modified cell cycle pathways and
altered vulnerability of axonal and synaptic compartments in
postmitotic, terminally differentiated neurons.
Results
Increased expression of cell cycle genes and proteins in 
Wlds-expressing cells in vivo and in vitro
We used cell cycle pathway-specific RT2 profiler PCR arrays
(see Materials and methods [below]) to quantify and compare
the expression of cell cycle-related genes with high sensitivity.
Initially, we used RNA extracted from the cerebellum of wild-
type and Wlds mice because this tissue has proven ideal for
comparative genomic experiments [22]. Wlds cerebellar gran-
ule cells are also known to express Wlds protein at high levels
and exhibit a strong neuroprotective phenotype [22]. We
compared expression levels of 84 genes that regulate the cell
cycle, including transitions between each of the phases, DNA
replication, checkpoints, and arrest. Seventeen out of the 84
genes examined (around 20%) had expression levels
increased by more than twofold in Wlds cerebellum (Figure 1
and Table 1). The array identified changes in genes associated
with many different stages of the cell cycle rather than one
specific stage (Table 1). Interestingly, no cell cycle related
genes appeared to be suppressed greater than twofold by
Wlds (Figure 1 and Table 1).http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.3
Genome Biology 2008, 9:R101
To confirm that RNA changes led to corresponding changes
in protein levels, we quantified protein expression levels in
the cerebellum of Wlds and wild-type mice in vivo. We chose
to focus on one of the genes with a large RNA change and one
with a smaller change, just above the twofold threshold,
where good antibodies were available (cABL and Brca2,
respectively; Table 1). The protein product for both of these
genes exhibited corresponding increased expression levels, of
a similar ratio to that seen for RNA (Figure 2). In addition, we
examined protein levels of other known cell cycle regulators
to show that the changes observed on the PCR arrays were not
exclusive. Three of the four additional proteins examined
(histone H2B, BRCA1, and phosphohistone H2Ax) exhibited
significantly increased expression levels in Wlds cerebellum,
which is in keeping with the general trend observed on the
PCR arrays (Figure 2).
Next, we established that protein levels of two other cell cycle
regulators, not included on the PCR array chip but previously
shown to be modified in Wlds neurons, were similarly altered.
P r e v i o u s  s t u d i e s  h a v e  d e m o n s t r a t e d  t h a t  p r o t e i n  l e v e l s  o f
Ube1 (a protein with known cell cycle involvement [33-36])
are increased in Wlds synapses [31], and we were able to con-
firm this finding by showing increased total Ube1 protein lev-
els in Wlds  cerebellum (Figure 2). In addition,
immunocytochemical staining for Ube1 confirmed increased
nuclear expression levels in Wlds-expressing neurons in vivo
(Figure 3). We also found that Pttg1 protein levels (another
Up-regulation of cell cycle genes in terminally differentiated neurons from Wlds mouse cerebellum in vivo Figure 1
Up-regulation of cell cycle genes in terminally differentiated neurons from Wlds mouse cerebellum in vivo. Three-dimensional bar chart taken from 
SuperArray analysis software (cell cycle specific SuperArray; see Materials and methods) showing fold difference in expression levels for 84 cell cycle 
related genes, comparing wild-type cerebellum (control sample) with Wlds cerebellum (test sample). Individual genes with greater than twofold expression 
change can be found in Table 1.Genome Biology 2008, 9:R101
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protein that regulates cell cycle pathways [32]) were signifi-
cantly increased in Wlds cerebellum (Figure 2), which is in
keeping with changes in all other cell cycle regulators modi-
fied by Wlds. This result was surprising because although
Pttg1 protein levels had not previously been examined in
Wlds-expressing cells, several previous reports have identi-
fied reduced mRNA levels for Pttg1 [22,30].
To verify that the alterations in cell cycle gene expression
were occurring as a direct result of the presence of Wlds, and
to further confirm that RNA changes observed in Wlds mouse
cerebellum led to corresponding changes in protein levels, we
examined the effects of Wlds on cell cycle in human embry-
onic kidney (HEK293) cells after transfection with enhanced
green fluorescent protein (eGFP)-tagged Wlds  constructs
[22]. We selected HEK293 cells for our experiments for two
m a i n  r e a s o n s .  F i r s t ,  w e  w a n t e d  t o  c o n s i d e r  w h e t h e r  t h e
expression changes observed in mouse neurons in vivo could
be replicated in a human cell line, as has previously been
demonstrated for other Wlds-mediated changes in gene
expression [22]. Second, HEK293 cells are an experimentally
amenable, homogenous cell line that is routinely used to
study transcriptional effects [22,50] and to model degenera-
tive mechanisms in the human nervous system [51,52].
As for the cerebellar experiments, we again chose initially to
focus on one gene with a large RNA change (Abl1) and one
with a change just above the twofold threshold (Brca2). The
protein product for both of these genes exhibited correspond-
ing increased expression levels, of a similar ratio to that seen
for RNA (Figure 4). In addition, we once again examined
protein levels of other known cell cycle regulators to show
that the changes observed on the PCR arrays were not exclu-
sive. All four additional proteins examined (HDAC2, histone
H2B, acetyl histone H3, and phosphohistone H2Ax) showed
increased expression levels in Wlds-transfected cells, which is
in keeping with the general trend observed on the PCR arrays
(Figure 1). These experiments also provided further confir-
mation that both Ube1 and Pttg1 protein levels are increased
by Wlds expression (Figure 4; compare with Figures 2 and 3).
Because the Wlds protein is known to have a predominantly
nuclear distribution [20,21], and most cell cycle proteins
modulate cell cycle via interactions in the nucleus, we next
tested whether Wlds expression altered the nuclear expres-
sion of cell cycle proteins. We chose to investigate the nuclear
distribution of phosphohistone H2Ax in Wlds-transfected
HEK293 cells because this protein has a well-established role
in the cell cycle [53,54] and was among the largest protein
changes identified in HEK293 cells (Figure 5; see Figures 2
and 4 for phosphohistone H2Ax protein levels in vivo and in
vitro). Not all cells express Wlds  using our transfection
protocol, as identified by the presence of an eGFP signal (Fig-
ure 5b,e). We were therefore able to compare directly
Table 1
Mouse SuperArray data showing greater than twofold cell cycle RNA expression changes in the cerebellum of Wlds mice compared with 
wild-type controls
Gene name Symbol Acc. Number Array cell Fold change SD Cell cycle function
V-abl Abelson murine leukemia oncogene 1 Abl1 NM_009594 A01 21.91 1.74 Regulation
Cyclin B1 Ccnb1 NM_172301 A12 5.50 0.65 M phase and regulation
Antigen identified by monoclonal antibody 
Ki 67
Mki67 XM_133912 D09 4.23 0.41 S phase and DNA replication
Cyclin A2 Ccna2 NM_009828 A11 3.85 0.65 Regulation
G protein-coupled receptor 132 Gpr132 NM_019925 C11 3.73 0.82 G1 phase and G1/S transition
Checkpoint kinase 1 homolog Chek1 NM_007691 C01 2.74 0.81 G2 phase and G2/M transition
Transformation related protein 63 Trp63 NM_011641 G10 2.53 0.06 Negative regulator
Cyclin-dependent kinase 2 Cdk2 NM_016756 B07 2.43 0.52 M phase
Calcium/calmodulin-dependent protein 
kinase II, beta
Camk2b NM_007595 A08 2.41 0.10 G1 phase and G1/S transition
S-phase kinase-associated protein 2 (p45) Skp2 NM_013787 F12 2.40 0.26 G1 phase and G1/S transition and 
regulation
Wee 1 homolog Wee1 NM_009516 G12 2.33 0.02 M phase
Meiotic recombination 11 homolog A Mre11a NM_018736 D10 2.28 0.57 S phase and DNA replication
CDC28 protein kinase 1b Cks1b NM_016904 C02 2.23 0.49 Checkpoint and arrest and regulation
Breast cancer 2 Brca2 NM_009765 A06 2.23 0.63 M phase and regulation and checkpoint 
and arrest
Cyclin C Ccnc NM_016746 B02 2.07 0.12 regulation
Transcription factor Dp 1 Tfdp1 NM_009361 G07 2.07 0.06 Regulation
SMT3 suppressor of mif two 3 homolog 1 Sumo1 NM_009460 G04 2.04 0.13 S phase and DNA replication
Retinoblastoma-like 2 Rbl2 NM_011250 F08 2.01 0.25 Negative regulator
SD, standard deviation.http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.5
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experimental cells expressing Wlds or eGFP-only controls
with neighbouring nontransfected cells. Anti-phosphohis-
tone H2Ax antibodies revealed intense nuclear spots of phos-
phohistone H2Ax in all cells expressing Wlds (Figure 5a-f).
However, neighbouring cells not expressing Wlds did not
show any phosphohistone H2Ax nuclear puncta. No phos-
phohistone H2Ax staining was observed in control cells trans-
fected with eGFP, indicating that the response was not simply
the result of a large accumulation of foreign protein in the
nucleus (Figure 5g-i).
Because we had found that a broad spectrum of cell cycle
genes and proteins were modified by Wlds (Table 1), we next
tested whether Wlds can influence neurons to pass through
the complete cell cycle by quantifying proliferation rates in a
human neuronal cell line (NT2 cells) using an MTT (3-[4,5-
dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide)
assay. Introduction of a Wlds construct into NT2 cells did not
modify cell proliferation rates compared with vector-only
transfected cells, either at 48 or 72 hours after transfection, or
at low, medium, or high doses (Figure 6a-b). These findings
were confirmed using tritiated thymidine uptake assays
where values were normalized to low dose treatment (mean
count: 14,770 ± 1,259 disintegrations per minute [DPM]; Fig-
ure 6c). Tritiated thymidine uptake assays were performed at
48 hours post-transfection in order to corroborate data from
MTT assays generated at the same experimental time point
and because this was the time point anticipated to give the
maximum chance of detecting a proliferative change in these
cells. These data suggest that Wlds upregulates the expression
of a broad range of cell cycle regulators, pushing cells toward
cell cycle re-entry, but that pathways influencing later stages
of the cycle, such as mitotic cell division, remain inhibited.
In order to confirm that Wlds-mediated changes in cell cycle
genes/proteins were pushing terminally differentiated neu-
rons toward cell cycle re-entry rather than inhibiting cell cycle
activation, we compared the profile of Wlds-mediated protein
changes with changes induced by a well known pharmaco-
logic inhibitor of the cell cycle: the cyclin-dependent kinase
inhibitor flavopiridol. Treatment of HEK293 cells with fla-
vopiridol at an established active concentration (10 μmol/l
[48]) resulted in suppression of six out of eight cell cycle pro-
teins that were increased in Wlds-transfected HEK293 cells
(Figure 7). Thus, pharmacologic inhibition of the cell cycle
also induced changes in cell cycle proteins known to be
altered by Wlds, but importantly these changes in expression
levels occurred in the opposite direction. These data con-
firmed that Wlds reactivates dormant cell cycle pathways,
pushing cells toward cell cycle re-entry rather than inhibiting
it.
Role of Pttg1, NAD, and VCP pathways in mediating 
cell cycle modulation
After demonstrating that the Wlds gene robustly modifies cell
cycle status in a variety of cell types in vivo and in vitro, we
next investigated whether any of the previously identified
downstream modifications induced by Wlds play a role in
mediating cell cycle changes. First we investigated whether
Pttg1 alone, as a known regulator of G1 to S phase cell cycle
transition [32] with increased protein levels in Wlds-express-
ing cells (see Figures 2 and 4), was capable of mediating Wlds-
induced effects on cell cycle proteins. We compared expres-
sion levels of four previously highlighted cell cycle proteins
following transfection of HEK293 cells with either a Wlds con-
struct [22] or a Pttg1 over-expression construct [55] (Figure
8a). Three of the four proteins examined were not modified
by Pttg1 expression alone (Figure 8a), suggesting that other
pathways are also required to induce the full range of cell
cycle related changes (see below). However, Ube1 upregula-
tion was induced by Pttg1 over-expression to a similar extent
as seen with Wlds. This suggests that elevated Ube1 protein
levels previously reported in Wlds synapses [31] are occurring
downstream from increases in Pttg1 protein levels.
Pttg1 is currently the only known physiological substrate for
the E4 ubiquitination factor Ube4b [56], which is one of the
constituent parts of the chimeric Wlds gene [13]. In order to
establish whether the ability of Pttg1 to be ubiquitinated is
important for the regulation of Ube1, we repeated the
Quantitative fluorescent Western blots validate changes in cell cycle  proteins in Wlds cerebellum in vivo Figure 2
Quantitative fluorescent Western blots validate changes in cell cycle 
proteins in Wlds cerebellum in vivo. Bar chart showing percentage change in 
protein expression (mean ± standard error of the mean; n ≥ 3 for all 
proteins) in Wlds cerebellum compared with wild-type. As expected, Wlds 
protein expression was highly upregulated (left bar). The second portion 
of the graph shows increases in both pituitary tumor transforming gene 1 
(Pttg1) and ubiquitin-activating enzyme E1 (Ube1) proteins in Wlds mice, 
both of which have previously been implicated in the Wlds neuroprotective 
phenotype [22,31]. The third portion of the graph shows validation for 
two genes highlighted on the SuperArray analysis as being upregulated by 
more than twofold. The final portion of the graph shows similar increases 
in cell cycle proteins not included on the SuperArray plate, showing that 
increased expression of cell cycle proteins is not restricted to those 
included on the SuperArray. Statistical tests were carried out comparing 
raw expression data from wild-type mice with those from Wlds mice. **P < 
0.01, P < 0.001 by unpaired t-test (two-tailed). ns, not significant.Genome Biology 2008, 9:R101
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experiment using an over-expression construct containing a
non-ubiquitinatable form of Pttg1 [57]. The inability to be
ubiquitinated completely abolished the ability of Pttg1 to
increase Ube1 protein levels (Figure 8b), showing that ubiqui-
tination of Pttg1 by Ube4b (and/or other proteins in the ubiq-
uitin pathway) is likely to be important for Wlds-mediated cell
cycle changes.
Next, we investigated whether NAD-dependent pathways
play a role in mediating cell cycle changes, because several
recent studies have suggested that the Nmnat1 portion of the
chimeric Wlds gene plays a significant role in conferring a
neuroprotective phenotype by elevating NAD levels and
increasing sirtuin activity [23-25]. To examine whether NAD
pathways influence cell cycle changes observed in Wlds-
expressing cells, we performed cell cycle pathway specific RT2
profiler PCR arrays (using human rather than mouse arrays;
see Materials and methods [below]) on HEK293 cells treated
with 1 mmol/l NAD applied exogenously to the culture
medium. This NAD treatment has previously been shown to
Immunocytochemistry confirms increased nuclear expression of Ube1 in Wlds mouse cerebellum Figure 3
Immunocytochemistry confirms increased nuclear expression of Ube1 in Wlds mouse cerebellum. Confocal micrographs of cerebellar granule cells from 
(a-c) Wlds and (d-f) wild-type mice. Ubiquitin-activating enzyme E1 (Ube1) is shown in green and the nuclear marker TOPRO3 is shown in blue (panels a 
and d show Ube1; panels b and e show TOPRO3; and panels c and f show both markers). Note how Ube1 protein appears to be more strongly expressed 
in the nuclei of Wlds cerebellar neurons, whereas TOPRO3 and cytoplasmic levels of Ube1 appear unchanged. (g-i) Scatter plots (line indicates mean) of 
fluorescence intensity (see Materials and methods) of nuclear Ube1 (panel g), nuclear TOPRO3 (panel h), and cytoplasmic Ube1 (panel i). Only nuclear 
Ube1 was significantly increased in intensity in Wlds neurons (P < 0.001; by unpaired, two-tailed t-test). Scale bar 20 μm.http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.7
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confer axonal protection in vitro [23] and to mediate selected
Wlds-induced transcriptional changes [22]. Forty-eight out of
the 84 genes examined exhibited greater than twofold
changes in expression after NAD treatment. In a similar
result to that obtained in the Wlds mouse cerebellar array
experiments, the vast majority (47 out of the 84) of modified
genes had increased expression levels in the NAD treated cells
(Figure 9 and Table 2). Only one cell cycle related gene
appeared to be suppressed greater than twofold by NAD (Fig-
ure 9). A direct comparison of SuperArray data from Wlds cer-
ebellum and NAD-treated HEK293 cells showed changes of a
similar magnitude for eight out of the nine genes examined
(Figure 10a; only nine candidate genes could be directly com-
pared due to their presence/alteration on both arrays).
Increases in protein expression levels of Pttg1, BRCA2,
BRCA1, and H2Ax in NSC34 cells treated with 1 mmol/l NAD
for 4 days confirmed that these NAD-induced changes extend
beyond those included on the SuperArray, extend to the pro-
tein level, and can occur in neuronal cells (Figure 10b). These
data suggest that elevated exogenous NAD levels can mimic
many, but importantly not all, Wlds-induced cell cycle
changes.
Alongside identified changes in Pttg1/Ube1 expression and
NAD pathways, previous studies have implicated VCP-medi-
ated pathways (also known as p97 and CDC48) in Wlds-medi-
ated neuroprotection, via its interaction with the Ube4b
component of the Wlds chimeric protein [28]. Moreover, VCP
is known to be important in early stages of cell cycle progres-
sion; VCP is normally localised in the endoplasmic reticulum
during nonproliferative states (for example, terminally differ-
entiated neurons), but relocates to the nucleus during late G1
phase in a cell cycle dependent manner [37]. Thus, VCP local-
isation would not normally be observed in the nucleus of ter-
minally differentiated neurons unless cell cycle had been
reactivated and they are progressing toward S phase. To
examine whether VCP redistribution associated with modi-
fied cell cycle status is modified by Wlds, we examined VCP
localization in the cerebellum of Wlds and wild-type mice.
These experiments revealed an expected cytoplasmic, non-
nuclear localization in wild-type neurons, but distinct, strong
nuclear puncta in most cerebellar granule cells in Wlds mice
(Figure 11). As predicted from the finding that VCP binds
Wlds [28], VCP localization in the nucleus was consistently
found in the same nuclear puncta as Wlds protein (Figure 11).
These data provide further evidence that Wlds-expressing
cells are being pushed toward the early phases of cell cycle re-
entry and suggest that VCP binding may play a role in this
process.
Thus, Pttg1/Ube1, NAD, and VCP pathways are all likely to be
involved in mediating Wlds-induced modifications in cell
cycle status. Taken together, these findings suggest that pre-
vious observations of apparently unrelated changes in gene
and protein expression/activity downstream of Wlds can in
fact be unified by their ability to modify the cell cycle.
Modifications in cell stress pathways induced by Wlds in 
vivo and in vitro
Changes in cell cycle status in terminally differentiated neu-
rons are often associated with corresponding changes in cell
stress pathways [58-60]. To examine whether cell stress path-
ways were also altered in Wlds-expressing cells, we used cell
stress pathway-specific RT2 profiler PCR arrays (see Materi-
als and methods [below]) to compare mRNA levels in the cer-
ebellum of wild-type and Wlds mice (Figure 12). Fourteen out
of the 84 genes contained on the array were modified greater
than twofold by Wlds, showing that a subset of cell stress
pathways are also modified in Wlds (Figure 12 and Table 3). In
contrast to the results from cell cycle arrays, however, Wlds
neurons revealed both increases and decreases across a range
of different cell stress proteins.
Quantitative fluorescent Western blots validate changes in cell cycle  proteins in Wlds-expressing HEK293 cells in vitro Figure 4
Quantitative fluorescent Western blots validate changes in cell cycle 
proteins in Wlds-expressing HEK293 cells in vitro. Bar chart showing 
percentage change in protein expression (mean ± standard error of the 
mean; n ≥ 3 for all proteins) in Wlds-transfected HEK293 cells compared 
with enhanced green fluorescent protein (eGFP)-transfected control cells. 
As expected, Wlds protein expression was highly upregulated (left bar). 
The second portion of the graph shows increases in both pituitary tumor 
transforming gene 1 (Pttg1) and ubiquitin-activating enzyme E1 (Ube1) 
proteins following Wlds transfection, both of which were previously 
implicated in the Wlds neuroprotective phenotype [22,31]. The third 
portion of the graph shows validation for two genes highlighted on the 
SuperArray analysis as being upregulated by more than twofold. The final 
portion of the graph shows similar increases in cell cycle proteins not 
included on the SuperArray plate, showing that increased expression of 
cell cycle proteins is not restricted to those included on the SuperArray. 
All genes were significantly increased in expression levels in Wlds-
transfected cells compared with control cells. **P < 0.01, ***P < 0.001 by 
unpaired t-test (two-tailed).Genome Biology 2008, 9:R101
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Finally, in order to confirm that Wlds altered nuclear localiza-
tion, as well as expression, of cell stress proteins (as for cell
cycle proteins shown in Figures 3 and 5), we investigated the
expression and distribution of stress-induced phosphopro-
tein 1 (STI1) in Wlds-transfected HEK293 cells (Figure 13).
We chose to use STI1 as a marker of cell stress in vitro in order
to expand our coverage of cell stress modifications beyond
those genes/proteins incorporated on the array chip and also
Increased expression of the cell cycle marker phosphohistone H2Ax in Wlds transfected HEK293 cells Figure 5
Increased expression of the cell cycle marker phosphohistone H2Ax in Wlds transfected HEK293 cells. Confocal micrographs of HEK293 cells 5 days after 
transfection with either an (a-f) enhanced green fluorescent protein (eGFP)-Wlds construct or (g-i) a eGFP-only control construct. Immunocytochemical 
labeling of phosphohistone H2Ax is shown in red, the nuclear marker TOPRO3 is shown in blue, and constructs are expressing in green (panels a, d and g 
show H2Ax and TOPRO3; panels b, e and h show construct and TOPRO3; and panels c, f and i show all three markers). Note how phosphohistone H2Ax 
protein can only be seen in nuclear puncta where Wlds is being expressed. Note that not all cells have transfected with construct, and non-Wlds expressing 
cells identifiable by their TOPRO3 labeled nuclei do not have corresponding H2Ax puncta. H2Ax puncta were found in all Wlds-expressing cells, regardless 
of the nuclear distribution of Wlds (panels a to c show Wlds in nuclear inclusions; panels d to f show Wlds expressed in a strong diffuse manner throughout 
the nucleus). Scale bar 10 μm.http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.9
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Wlds does not influence late stages of cell cycle regulating cell proliferation in NT2 cells Figure 6
Wlds does not influence late stages of cell cycle regulating cell proliferation in NT2 cells. Bar charts showing relative proliferation rates of NT2 cells 
transfected with either a control vector (black bars) or a Wlds vector (white bars) at low, medium, and high concentrations. (a) Panel a shows no 
difference in proliferation at 48 hours after transfection using an MTT (3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bromide) assay. (b) Panel b 
similarly shows no difference in proliferation at 72 hours after transfection using an MTT assay. (c) Panel c shows no difference in proliferation at 48 hours 
after transfection using a tritiated thymidine incorporation assay (all comparisons P > 0.05; analysis fo variance with Tukey's post hoc test).
Pharmacological inhibition of cell cycle progression (flavopiridol) versus Wlds: opposing changes in cell cycle proteins Figure 7
Pharmacological inhibition of cell cycle progression (flavopiridol) versus Wlds: opposing changes in cell cycle proteins. (a) Bar chart showing protein 
expression assayed by quantitative fluorescent western blots in HEK293 cells transfected with Wlds (black bars) or treated with exogenous flavopiridol (10 
μmol/l; cell cycle inhibitor). Whereas Wlds induced increases in all cell cycle proteins, flavopiridol treatment led to decreased expression of the majority of 
proteins examined. (b) Representative Western blots showing pituitary tumor transforming gene 1 (Pttg1) protein levels in HEK293 cells comparing 
control versus Wlds transfected cells (top panel) and control versus flavopiridol treated cells (bottom panel). Note how Pttg1 protein levels are increased 
by Wlds expression and decreased by flavopiridol treatment.Genome Biology 2008, 9:R101
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because STI1 protein levels are known to be modified in Wlds
synapses in vivo [31]. Anti-STI1 antibodies revealed nuclear
spots of STI1 in most cells expressing Wlds (Figure 13a-f).
However, neighbouring cells not expressing Wlds (because of
less than 100% transfection efficiency) did not show any STI1
nuclear puncta. No STI1 staining was seen in control cells
transfected with eGFP, indicating that stress responses were
not simply occurring due to the presence of a large amount of
foreign protein in the nucleus (Figure 13g-i). These findings
were supported by data from quantitative Western blotting of
STI1 protein levels in whole Wlds cerebellum in vivo, where
STI1 levels were increased by 71.6 ± 6.8% (mean ± standard
error of the mean; data not shown). Interestingly, we previ-
ously showed that STI1 protein levels are decreased in syn-
apses protected by the Wlds gene in vivo [31]. The finding that
nuclear STI1 immunoreactivity increases in Wlds transfected
HEK293 cells suggests that some stress proteins may exhibit
differential compartmental expression via redistribution
within Wlds-expressing neurons, rather than simply having
altered expression levels.
Discussion
Here, we show that a strong correlation exists between modi-
fied cell cycle pathways and altered vulnerability of axonal
and synaptic compartments in postmitotic, terminally differ-
entiated neurons. We have demonstrated that the neuropro-
tective  Wlds  chimeric gene leads to a robust increase in
expression of a broad spectrum of cell cycle-related genes in
terminally differentiated neurons. These changes are indica-
tive of an attempt to re-enter cell cycle in postmitotic neu-
rons. Cell cycle alterations were identified in cerebellar
neurons in vivo and could be replicated in HEK293 cell lines
in vitro. We demonstrate that NAD, Pttg1/Ube1, and VCP
pathways are all likely to be responsible for mediating distinct
subsets of these downstream changes. Data from prolifera-
tion assays showing that Wlds does not alter cell division or
proliferation rates suggests that terminally differentiated
neurons expressing Wlds are pushed toward cell cycle re-
entry, but do not go on to enter proliferation and growth
phases. We also show that expression of the Wlds gene leads
to modifications in endogenous cell stress pathways that are
likely to result from modifications in cell cycle status.
Contrary to previous suggestions that Wlds-expressing neu-
rons are 'normal', with the exception of a phenotype solely
affecting axonal degeneration pathways [1], our experiments
have revealed a novel cellular phenotype in Wlds-expressing
cells: modifications in cell cycle status. This finding brings
together diverse observations from several disparate studies
investigating  Wlds  mechanisms (changes in Pttg1/Ube1,
NAD, and VCP/p97 pathways), suggesting that modified cell
cycle status might be a common endogenous pathway
through which genomic and proteomic modifications down-
stream of Wlds can influence neuronal vulnerability.
Pttg1/Ube1 pathways
Several studies have shown, using a range of experimental
approaches and platforms, that Wlds robustly downregulates
expression of Pttg1 mRNA [22,30]. Pttg1 plays a well
established role in sister chromatid separation during mito-
sis, but recent data have identified an important additional
role as a regulator of G1 to S phase cell cycle transition [32]. In
the present study we showed that Pttg1 protein levels are
significantly increased in Wlds-expressing cells. The most
parsimonious explanation for the differences between protein
and mRNA levels is that decreases in mRNA are generated by
a compensatory, self-regulating feedback loop responding to
elevated levels of Pttg1 protein. Because Pttg1 is the only
known substrate for the Ube4b component of the Wlds gene
[56], it is tempting to speculate that elevated Pttg1 protein
levels result from abnormal ubiquitination and targeting for
degradation, caused by Wlds-mediated alterations in the
ubiquitin-proteasome pathway [28,29]. This finding also has
implications for previous attempts to directly link Pttg1 to
neuroprotection, because earlier studies examined neurode-
generative responses in Pttg1 null mice [22]. The current data
suggest that repeating these experiments in Pttg1 over-
Over-expression of ubiquitinatable Pttg1 is required to elicit changes in  the cell cycle protein Ube1 Figure 8
Over-expression of ubiquitinatable Pttg1 is required to elicit changes in 
the cell cycle protein Ube1. Presented are quantitative fluorescent 
Western blots of HEK293 cells (n = 3 for all proteins). (a) Changes in four 
cell cycle proteins known to be modified by Wlds after transfection with 
either a Wlds construct (black bars) or a pituitary tumor transforming gene 
1 (Pttg1) over-expression construct (white bars). The first portion of the 
graph shows normalized Pttg1 levels accounting for differences in 
transfection efficiency. Note how Pttg1 induced the same level of increase 
in ubiquitin-activating enzyme E1 (Ube1) expression as Wlds but had no 
effect on the three other proteins. (b) changes in Ube1 can only be 
induced by a ubiquitinatable form of Pttg1, because transfection with a 
non-ubiquitinatable form of Pttg1 (gray bars) could not elicit any changes 
in Ube1 expression (right portion of graph).http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.11
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expressing mice might reveal a neuroprotective phenotype,
although the undoubted contribution made by other path-
ways (see below) suggests that Pttg1 over-expression alone
would be unlikely to confer the full levels of Wlds-mediated
neuroprotection.
We have also shown that increased Pttg1 protein levels
induced by Wlds are responsible for mediating corresponding
increases in expression of another cell cycle-related protein,
namely Ube1. Thus, Pttg1 is likely to be a partial mediator of
other cell cycle changes induced by Wlds. We previously
identified increased protein levels of Ube1 in a population of
striatal synapses from Wlds mice known to be protected from
degeneration [31], suggesting that Ube1 may also play a role
in directly modulating degenerative pathways in synaptic
compartments of neurons. Importantly, we also found that
the ability of Pttg1 to increase Ube1 protein levels was
abolished if Pttg1 was expressed in a non-ubiquitinatable
form. Because Pttg1 is the only known substrate for the Ube4b
component of the Wlds gene [56], these data suggest that
modified ubiquitination of Pttg1 by Ube4b (either in its native
form or as part of the Wlds protein) is likely to be required to
mediate downstream changes in proteins such as Ube1. How-
ever, at this stage we cannot rule out the possibility that other
proteins in the ubiquitin pathway alongside Ube4b are also
responsible for mediating this response.
NAD pathways
The most convincing evidence to date for the involvement of
a single pathway in downstream mediation of the Wlds phe-
Upregulation of cell cycle genes in HEK293 cells treated with 1 mmol/l exogenous NAD Figure 9
Upregulation of cell cycle genes in HEK293 cells treated with 1 mmol/l exogenous NAD. Three-dimensional bar chart taken from SuperArray analysis 
software (cell cycle SuperArray; see Materials and methods) showing fold difference in expression levels for 84 cell cycle related genes comparing vehicle 
treated HEK293 cells (control sample) with nicotinamide adenine dinucleotide (NAD) treated HEK293 cells (test sample). Individual genes with a greater 
than twofold expression change can be found in Table 2. NAD, nicotinamide adenine dinucleotide.Genome Biology 2008, 9:R101
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notype has come from studies showing that the Nmnat1 por-
tion of the chimeric Wlds gene confers a neuroprotective
phenotype via modulation of NAD levels [23-25]. Here, we
have shown that experimental manipulation of NAD levels
mimics many (but by no means all) of the cell cycle changes
induced by Wlds. This finding raises the possibility that at
least part of the NAD-mediated neuroprotective phenotype is
generated by modulating cell cycle status. This suggestion is
supported by several studies demonstrating that sirtuin-
dependent pathways (which mediate the NAD
neuroprotective phenotype [23]) play important roles in reg-
ulating cell cycle [38-40]. However, as with the Pttg1 findings
discussed above, it is unlikely that NAD-mediated changes
alone are sufficient to induce the full range of Wlds-mediated
cell cycle changes, because NAD over-expression alone is not
thought to be sufficient to confer the full neuroprotective phe-
notype in vivo or in vitro [26,27].
VCP/p97 pathways
Alongside Pttg1 and NAD, pathways mediated by VCP (also
known as p97 and CDC48) have also been shown to influence
cell cycle [61]. For example, although VCP is predominantly a
cytoplasmic protein, it is known to enter the nucleus during
late G1 phase [37]. Here, we have shown that VCP, which is
currently the only known binding partner for the Ube4b por-
tion of Wlds [28,62], is localized to the nucleus in the majority
of Wlds-expressing neurons. This is further corroborating evi-
dence that cell cycle has been reactivated in terminally
differentiated  Wlds neurons and that they are progressing
toward (or beyond) S phase. Although binding to VCP has not
yet been demonstrated to be required for the Wlds phenotype,
the present study suggests that if this is an important event,
VCP may be acting via regulation of the cell cycle in a similar
manner to Pttg1. Cell cycle events potentially attributable to
VCP pathways detected in the current experiments include
changes in expression levels of BRCA proteins that are known
to interact with VCP in the nucleus [63].
Cell cycle pathways and neurodegeneration
The hypothesis that Wlds may be modifying neurodegenera-
tive pathways in axons and synapses via modulation of the
cell cycle is in keeping with other literature on somatic neuro-
degeneration, in which cell cycle is known to influence vul-
nerability significantly. For example, it is now known that
postmitotic, terminally differentiated neurons in the adult
nervous system are not 'permanently postmitotic', but rather
depend upon the constant suppression of cell cycle pathways
to maintain their arrested status [41]. The ability to control
cell cycle pathways is therefore a critical factor in stopping
neurons entering a vulnerable state, where the risk for neuro-
degenerative mechanisms being instigated increases signifi-
cantly [41-44]. Numerous examples of cell cycle regulation
gone awry, modifying neuronal vulnerability, can be found in
neurodegenerative conditions such as motor neuron disease,
Alzheimer's disease, and stroke [45,46]. Furthermore, phar-
macologic manipulation of cell cycle progression has been
used to confer somatic neuroprotection in animal models of
traumatic brain injury and stroke [47,48]. The current data
suggest that the influence of cell cycle status on neuronal
vulnerability is likely to extend beyond neurodegenerative
mechanisms resident in cell soma to incorporate independent
degenerative pathways in axonal and synaptic compartments.
The  Wlds  gene may therefore provide an important
experimental tool for future investigations into pathways
through which cell cycle status modulates neuronal
vulnerability.
The current data are also likely to be important for interpret-
ing previous and future studies concerning Wlds-mediated
neuroprotection both in vivo and  in vitro. Because
endogenous cell cycle and cell stress pathways are robustly
modified by Wlds expression, it is difficult to imagine that
Wlds-expressing cells do not have any other covert cellular
phenotypes alongside neuroprotection. These may introduce
additional variables that could conceivably alter experimental
outcomes (for example, comparing Nmnat over-expressing
NAD-induced changes in cell cycle genes mimic Wlds-induced changes Figure 10
NAD-induced changes in cell cycle genes mimic Wlds-induced changes. (a) 
Bar chart showing greater than twofold changes in cell cycle genes from 
SuperArray experiments on Wlds cerebellum (black bars; see Table 1) 
compared with nicotinamide adenine dinucleotide (NAD) treated HEK293 
cells (white bars; see Table 2). Of the nine genes examined, eight 
responded similarly in both experimental groups. (b) Bar chart showing 
percentage difference in protein expression in NSC34 cells treated with 1 
mmol/l exogenous NAD as compared with control-treated cells.http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.13
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Table 2
Human SuperArray data showing greater than twofold cell cycle RNA expression changes in NAD-treated HEK293 cells compared with 
controls
Gene name Symbol Acc. Number Array cell Fold change SD Cell cycle function
V-abl Abelson murine leukemia viral 
oncogene homolog 1
ABL1 NM_005157 A01 18.25 3.19 S phase and DNA replication and 
regulation
Cullin 2 CUL2 NM_003591 D10 14.32 1.89 G1 phase and G1/S transition and 
checkpoint and arrest
B-cell CLL/lymphoma 2 BCL2 NM_000633 A09 12.44 2.12 Regulation
Cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4)
CDKN2B NM_004936 D03 11.03 2.37 Checkpoint and arrest and negative 
regulator
Anaphase promoting complex subunit 4 ANAPC4 NM_013367 A03 9.17 0.27 G2 phase and G2/M transition and 
regulation
Cullin 3 CUL3 NM_003590 D11 8.46 0.65 G1 phase and G1/S transition and 
checkpoint and arrest
Cyclin-dependent kinase 5, regulatory 
subunit 1 (p35)
CDK5R1 NM_003885 C07 8.00 1.66 Regulation
RAD1 homolog RAD1 NM_002853 F09 7.43 0.48 Checkpoint and arrest
SERTA domain containing 1 SERTAD1 NM_013376 G06 7.41 0.27 G2 phase and G2/M transition
Ataxia telangiectasia and Rad3 related ATR NM_001184 A06 6.51 0.36 Checkpoint and arrest
Ubiquitin-activating enzyme E1 UBE1 NM_003334 G12 6.48 1.19 S phase and DNA replication
Dynamin 2 DNM2 NM_004945 E01 5.38 0.37 G2 phase and G2/M transition
Cell division cycle 16 homolog CDC16 NM_003903 C01 4.94 0.43 M phase
HUS1 checkpoint homolog HUS1 NM_004507 E07 4.89 0.74 Checkpoint and arrest
Cyclin-dependent kinase 8 CDK8 NM_001260 C11 4.86 1.25 Regulation
RAD51 homolog (RecA homolog) RAD51 NM_002875 F11 4.77 3.09 M phase
Menage a trois homolog 1, cyclin H 
assembly factor
MNAT1 NM_002431 F05 4.51 0.18 G2 phase and G2/M transition
Tumor protein p53 (Li-Fraumeni 
syndrome)
TP53 NM_000546 G11 4.40 1.48 Checkpoint and arrest
Cyclin-dependent kinase 2 CDK2 NM_001798 C05 4.07 0.24 Checkpoint and arrest and regulation
Anaphase promoting complex subunit 2 ANAPC2 NM_013366 A02 3.76 0.63 G1 phase and G1/S transition and regulation
Growth arrest and DNA-damage-
inducible, alpha
GADD45A NM_001924 E03 3.70 0.08 Checkpoint and arrest and regulation
Cyclin-dependent kinase inhibitor 1B 
(p27, Kip1)
CDKN1B NM_004064 D01 3.65 0.25 G1 phase and G1/S transition and 
checkpoint and arrest
Cyclin-dependent kinase inhibitor 3 CDKN3 NM_005192 D04 3.36 0.09 G1+G2 phase and G1/S + G2/M transition 
and checkpoint and arrest
CDK5 regulatory subunit associated 
protein 1
CDK5RAP1 NM_016408 C08 3.32 0.06 G2 phase and G2/M transition
Cyclin F CCNF NM_001761 B07 3.22 0.20 M phase and regulation
Cyclin-dependent kinase 6 CDK6 NM_001259 C09 3.22 0.23 G1 phase and G1/S transition and regulation
DIRAS family, GTP-binding RAS-like 3 DIRAS3 NM_004675 A04 3.15 0.12 ?
CHK1 checkpoint homolog CHEK1 NM_001274 D05 2.95 0.15 Checkpoint and arrest
Nibrin NBN NM_002485 F07 2.89 0.03 Checkpoint and arrest
Retinoblastoma-like 2 (p130) RBL2 NM_005611 G04 2.89 0.83 Negative regulator
Cell division cycle 34 homolog CDC34 NM_004359 C04 2.86 0.14 G1 phase and G1/S transition and 
checkpoint and arrest
Cyclin G2 CCNG2 NM_004354 B09 2.81 0.18 Checkpoint and arrest
BCL2-associated X protein BAX NM_004324 A07 2.76 0.06 Negative regulator
Proliferating cell nuclear antigen PCNA NM_182649 F08 2.76 0.19 S phase and DNA replication
SMT3 suppressor of mif two 3 homolog 
1
SUMO1 NM_003352 G08 2.73 0.10 S phase and DNA replication
Cyclin-dependent kinase inhibitor 1A 
(p21, Cip1)
CDKN1A NM_000389 C12 2.67 0.08 Checkpoint and arrest and regulationGenome Biology 2008, 9:R101
http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.14
Hect domain and RLD 5 HERC5 NM_016323 E06 2.54 0.04 G2 phase and G2/M transition
Cyclin-dependent kinase 4 CDK4 NM_000075 C06 2.52 0.13 G1 phase and G1/S transition and regulation
G-2 and S-phase expressed 1 GTSE1 NM_016426 E05 2.49 0.10 G2 phase and G2/M transition
Cyclin T2 CCNT2 NM_001241 B12 2.41 0.16 G2 phase and G2/M transition and 
regulation
Breast cancer 2, early onset BRCA2 NM_000059 A12 2.36 0.27 Checkpoint and arrest and regulation
Retinoblastoma-like 1 (p107) RBL1 NM_002895 G03 2.31 0.04 Negative regulator
MCM5 minichromosome maintenance 
deficient 5
MCM5 NM_006739 F03 2.28 0.13 S phase and DNA replication
CDC28 protein kinase regulatory 
subunit 1B
CKS1B NM_001826 D07 2.28 0.03 G2 phase and G2/M transition and 
regulation
Cell division cycle 20 homolog CDC20 NM_001255 C03 2.24 0.17 Regulation
Cyclin C CCNC NM_005190 B03 2.16 0.14 Regulation
MAD2 mitotic arrest deficient-like 2 MAD2L2 NM_006341 E11 2.03 0.46 Checkpoint and arrest
Transcription factor Dp-1 TFDP1 NM_007111 G09 -22.50 1.04 Regulation
NAD, nicotinamide adenine dinucleotide; SD, standard deviation.
Increased nuclear expression of cell cycle marker VCP corresponding with Wlds expression in mouse cerebellum Figure 11
Increased nuclear expression of cell cycle marker VCP corresponding with Wlds expression in mouse cerebellum. Confocal micrographs of cerebellar 
granule cells from (a-c) Wlds and (d-f) wild-type mice. Valosin-containing protein (VCP) is shown in green, the nuclear marker TOPRO3 is shown in blue, 
and Wlds protein in red (panels a and d show VCP and TOPRO3; panels b and e show Wlds and TOPRO3; and panels c and f show all three markers). 
Note how VCP protein can be seen in nuclear puncta with high frequency where Wlds is being expressed (arrows in panels a and c show four out of nine 
examples in this field of view). The majority of Wlds puncta coincided with VCP puncta. Nuclear puncta of VCP were rarely observed in wild-type 
cerebellar granule cells. As expected, VCP was detectable as diffuse staining in the cytoplasm of neurons in both strains of mice. Scale bar = 20 μm.
Table 2 (Continued)
Human SuperArray data showing greater than twofold cell cycle RNA expression changes in NAD-treated HEK293 cells compared with 
controlshttp://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.15
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cells in vivo with cells exposed to exogenous NAD in vitro
[23-27]).
Current opinion suggests that cell cycle re-entry is damaging
to neurons, whereas blocking cell cycle decreases vulnerabil-
ity [41-44]. The finding that the neuroprotective Wlds gene
pushes neurons toward cell cycle re-entry therefore appears
at odds with this hypothesis. There are two possible
explanations for this discrepancy. First, it is possible that the
basic principle of re-entry is bad/suppression is good may not
hold for all neurodegenerative pathways. Second, and per-
haps more plausibly, it is possible that Wlds acts to 'prime' the
cell against future neurodegenerative insults by inducing
early-stage cell cycle changes - and cell stress modifications -
without going as far as affecting proliferation and growth
stages. This potential mechanism of action is in keeping with
a known role for preconditioning, sublethal 'priming' events
in conferring neuroprotection by modifying endogenous
stress pathways [64-67].
Cell stress pathways and Wlds
Our finding that cell stress pathways are also modified in
Wlds mice, suggesting a possible 'primed state' of Wlds neu-
rons, is in keeping with the findings of other recent studies.
For example, it was recently demonstrated that the NMNAT1
component of the chimeric Wlds gene has functions alongside
those involving NAD, acting as a chaperone for stress-
response proteins such as heat shock protein-70 [68]
(Wishart TM, Gillingwater TH, unpublished observations). In
addition, we have recently shown that the mitochondrial
Widespread alterations in cell stress genes in uninjured/untreated Wlds mouse cerebellum in vivo Figure 12
Widespread alterations in cell stress genes in uninjured/untreated Wlds mouse cerebellum in vivo. Three-dimensional bar chart taken from SuperArray 
analysis software (cell stress SuperArray; see Materials and methods) showing fold difference in expression levels for 84 cell stress related genes 
comparing wild-type cerebellum (control sample) with Wlds cerebellum (test sample). Individual genes with a greater than twofold expression change can 
be found in Table 3.Genome Biology 2008, 9:R101
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proteome is modified at a basal level in protected Wlds syn-
apses [31], suggesting intrinsic differences in the ability to
respond to cell stress stimuli. This hypothesis has received
experimental support from another recent study showing that
NMNAT1 can protect against mitochondrial and oxidative
stress [69].
Our study has identified possible individual stress-related
proteins that may play an important role in the cell stress
response in Wlds neurons. Interestingly, several of these pro-
teins have already been implicated in other neuroprotective
situations. For example, STI1 - shown in previous work [31]
and the present study to have altered levels and subcellular
localization in Wlds-expressing cells - appears to play an
important role in neuroprotection and neuritogenesis [70] as
well as in cell proliferation [71,72]. Further investigations into
the in vivo role played by individual cell stress proteins mod-
ified by Wlds, such as STI1, in modulating neuronal pheno-
types may therefore provide important insights into
mechanisms underlying axonal and synaptic vulnerability.
Conclusion
We have identified a strong and robust correlation between
modified cell cycle pathways and altered vulnerability of
axonal and synaptic compartments in terminally differenti-
ated neurons by showing that the neuroprotective Wlds gene
modifies cell cycle and cell stress status in vivo and in vitro.
We conclude that Wlds-expressing cells have a potentially
important, previously unreported cellular phenotype that is
characterized by reactivation of normally suppressed cell
cycle pathways in terminally differentiated neurons. We pro-
pose that multiple NAD-, Pttg1/Ube1-, and VCP-dependent
pathways are likely to be required to modulate these cell cycle
changes. The data suggest that further investigations into the
role of cell cycle and cell stress status induced by Wlds are
likely to provide insights into mechanisms that regulate
axonal and synaptic degeneration in neurodegenerative
disease.
Materials and methods
Mouse tissue and cell lines/treatments
Natural mutant C57Bl6/WldS (WldS) mice and C57Bl/6 (wild
type) mice (all aged 6 to 8 weeks) were obtained from Harlan
Olac Laboratories (Bicester, UK) and housed within the ani-
mal care facilities in Edinburgh. Mice (minimum three mice
per experimental group) were killed by cervical dislocation
and the cerebellum was rapidly removed.
HEK293 and NSC34 (a mouse motor neuron-like cell line
[73]) cells were maintained in Dulbecco's modified Eagle's
medium with 10% fetal bovine serum and 1% penicillin/strep-
t o m y c i n  ( I n v i t r o g e n ,  C a r l s b a d ,  C A ,  U S A )  a t  3 7 ° C  i n  5 %
carbon dioxide. For transfection with eGFP-Wlds [22], Pttg1
[55], and non-ubiquitinatable Pttg1 [57], 5 mg of the DNA was
mixed with 10% (vol/vol) CaCl2. An equal volume of N,N-
bis(2-hydroxyethyl)-2-aminoethanesulfonic acid was added
and the solution gently dropped onto the HEK293 cell culture
[22]. For some experiments, 1 mmol/l NAD (Sigma-Aldrich,
Gillingham, UK) or 10 μmol/l Flavopiridol (obtained through
the National Cancer Institute, Rockville, MD, USA) was
added to the medium. All cells were incubated for 4 to 5 days
and were checked on a phase contrast microscope before
Table 3
Mouse SuperArray data showing greater than twofold cell stress RNA expression changes in the cerebellum of Wlds mice compared 
with wild-type controls
Gene name Symbol Acc. number Array cell Fold change SD Cell stress and toxicity function
Serine (or cysteine) peptidase inhibitor, clade E, 
member 1
Serpine1 NM_008871 G01 3.73 0.29 Inflammation
Interleukin 1 beta Il1b NM_008361 E11 3.69 0.82 Inflammation
Transformed mouse 3T3 cell double minute 2 Mdm2 NM_010786 F02 3.34 0.15 Growth arrest and senescence
Cytochrome P450, family 2, subfamily a, polypeptide 5 Cyp2a5 NM_007812 B08 2.92 0.48 Oxidative or metabolic stress
Fas ligand (TNF superfamily, member 6) Fasl NM_010177 C11 2.62 0.71 Apoptosis signaling
Bcl2-like 1 Bcl2l1 NM_009743 A04 -2.11 0.25 Apoptosis signaling
Cyclin C Ccnc NM_016746 A10 -2.44 0.46 Proliferation and carcinogenesis
Chemokine (C-C motif) ligand 21b Ccl21b NM_011124 A07 -3.37 0.25 Inflammation
Chemokine (C-C motif) ligand 4 Ccl4 NM_013652 A09 -3.86 0.40 Inflammation
Annexin A5 Anxa5 NM_009673 A01 -4.00 1.50 Apoptosis signaling
Ataxia telangiectasia mutated homolog (human) Atm NM_007499 A02 -4.99 0.70 DNA damage and repair
Caspase 1 Casp1 NM_009807 A05 -6.81 7.58 Apoptosis signaling
Cytochrome P450, family 3, subfamily a, polypeptide 
11
Cyp3a11 NM_007818 B12 -8.60 0.52 Oxidative or metabolic stress
Chemokine (C-C motif) ligand 3 Ccl3 NM_011337 A08 -9.50 2.39 Inflammation
eGFP, enhanced green fluorescent protein; SD, standard deviation.http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.17
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proceeding to either immunocytochemistry/microscopy or
extraction of protein and/or RNA (at least three cultures for
all transfections and treatments).
RNA and protein extraction
RNA was extracted from cerebella of age-matched and sex-
matched mice, or HEK293 cells, in tri-reagent (Sigma) in
Increased nuclear expression of cell stress marker STI1 corresponding with Wlds expression in HEK293 cells Figure 13
Increased nuclear expression of cell stress marker STI1 corresponding with Wlds expression in HEK293 cells. Confocal micrographs of HEK293 cells 
transfected with either an (a-f) enhanced green fluorescent protein (eGFP)-Wlds construct or an (g-i) eGFP alone control construct. Stress induced 
phosphoprotein 1 (STI1) is shown in red, the nuclear marker TOPRO3 is shown in blue, and Wlds protein in green (panels a, d and g show STI1 and 
TOPRO3; panels b, e and h show construct and TOPRO3; and c, f and i show all three markers). Note how STI1 protein can be seen in nuclear puncta 
with high frequency where Wlds is being expressed, but was never observed in non-Wlds-expressing cells. The majority of Wlds puncta coincided with STI1 
puncta. Nuclear puncta of STI1 were never observed in eGFP transfected control cells (panels g-i). Scale bar = 10 μm.Genome Biology 2008, 9:R101
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accordance with the manufacturer's instructions, as previ-
ously described [22]. Protein was extracted from cerebella of
age-matched and sex-matched mice, or HEK293 cells, in
R I P A  b u f f e r  w i t h  1 0 %  p r o t e a s e  i n h i b i t o r  c o c k t a i l  ( S i g m a )
[31].
Super arrays
Mouse cell cycle (PAMM-020A), cell stress (PAM-003A), and
human cell cycle (PAHS-020A) focused pathway arrays
(Tebubio Superarrays, Peterborough, UK) in 96-well plate
format, compatible with an ABI 7000 real-time PCR
machine, were used to assay gene expression changes (three
comparisons for each array type). Samples were added to the
reaction plates and signal amplification by PCR was carried
out using a Sybr-Green '1 step qRT-PCR kit' (Invitrogen).
Analysis was carried out using the Analysis Suite spreadsheet
provided by Tebubio Superarrays. The absence of DNA con-
tamination and efficiency of amplification was confirmed
using the analysis software provided. Gene functions listed in
Tables 1 to 3 were obtained from the SuperArray product
specification sheets. Raw data for all of these array experi-
ments can be found online [74].
Quantitative Western blots
Cerebellar/cultured cell protein was separated by SDS-PAGE
on 4% to 20% pre-cast NuPage 4% to 12% Bis Tris gradient
gels (Invitrogen) and then transferred to PVDF membrane
overnight. The membranes were then blocked using Odyssey
blocking buffer (Li-COR Biosciences, Lincoln, Nebraska,
USA) and incubated with primary antibodies as per manufac-
turers instructions (BRCA2, cAbl, CCL3 and E1 ubiquitin acti-
vating enzyme [Abcam, Cambridge, MA, USA]; anti-HDAC2
clone 3F3, anti-histone H2B and anti acetyl histone H3 [Lake
Placid Biologicals, Lake Placid, NY, USA]; Pds1 Ab1 clone
DCS280/Anti-Pttg1 [LabVision Corporation, Freemont, CA,
USA]; and antiphosphohistone H2Ax [Upstate, Billerica, MA,
USA]). Anti-Wlds antibodies were a kind gift from Dr Michael
Coleman and were used as previously described [20,21].
Odyssey secondary antibodies were added in accordance with
the manufacturer's instructions (Goat anti rabbit IRDye 680
and Goat anti mouse IRDye 800). Blots were imaged using an
Odyssey Infrared Imaging System (Li-COR Biosciences). The
scan resolution of the instrument ranges from 21 to 339 μm,
and in this study blots were imaged at 169 μm. Quantification
was performed on single channels with the analysis software
provided. Bands were identified according to their relative
molecular weight, as detailed in the manufacturer's antibody
notes. Bands were delineated using Odyssey software and the
arbitrary fluorescence intensity calculated by the software.
For each membrane, scans were carried out at three different
intensities in order to minimize possible user error in deter-
mining correct scan intensities or over-saturation of the
membrane. The average of these three separate scans (giving
an n of 1 per membrane) was used for further analysis.
NT2 cell proliferation assays
MTT assays were carried out in 96-well plates. One hundred
micrograms of MTT was added to 6,000 cells per well of NT2
cells transfected with control (vector only) or Wlds constructs
(200 ng [low dose], 600 ng [medium dose], and 1,200 ng
[high dose]), and incubated for 3 hours. Media were then
removed and formazan crystals dissolved in 50 μl dimethyl
sulfoxide. The absorbance of the dimethyl sulfoxide was read
at 545 nm to estimate cell number. For 3H-thymidine
incorporation assays, 3 × 105 NT2 cells per well of a 24-well
plate were transfected with control (vector only) or Wlds con-
structs, as detailed above, and proliferation assayed at 48
hours. Mitogenesis was estimated from the measurement of
nuclear 3H-thymidine incorporation. Cells were incubated
with 0.2 Ci 3H-thymidine (specific activity 70-95 Ci/mmol;
Amersham Biosciences, Little Chalfont, UK) for the last 5
hours of culture incubation. Cells were then washed twice in
ice-cold phosphate-buffered saline (PBS), followed by 1 ml
cold 5% trichloroaceteic acid, and left on ice for 20 minutes.
Then, 0.1 mol/l sodium hydroxide was added to the cells
before transfer to 4 ml of scintillant. Radioactive counts were
determined by scintillation counting. Experiments comprised
four replicates each and were performed on at least two sepa-
rate occasions.
Immunocytochemistry
Immunofluorescence staining was performed on either
freshly cut (20 μm or 100 μm) cerebellar slices or HEK293
cells, fixed in 4% paraformaldehyde (Fisher Scientific, Lough-
borough, UK). Slices or cultured cells were incubated over-
night in serum blocker consisting of 4% bovine serum
albumin (Sigma) and 0.5% Triton X-100 (Sigma) in PBS. In
cerebellar slices, anti-Wlds  antibodies (1:500 dilution in
serum blocking solution [8]) were applied overnight and,
after washing with PBS saline, a TRITC-conjugated anti-rab-
bit secondary antibody (DAKO, Glostrup, Denmark) was
applied overnight. Primary antibodies, including Ube1
(Abcam), VCP (Abcam), Sti1 (BD Transduction Laboratories,
San Jose, CA, USA), and phosphohistone H2Ax (Upstate),
were also used at concentrations specified by the manufactur-
ers. Anti-rabbit/mouse FITC-conjugated secondary antibod-
ies (DAKO) were used on cerebellar slices and anti-rabbit/
mouse TRITC-conjugated secondary antibodies (DAKO)
were used on HEK293 cells. Secondary antibody only con-
trols were also carried out and confirmed the specificity of
antibodies used (data not shown). Finally, cerebellar slices
and cultured cells were then washed in PBS and incubated in
TOPRO 3 (Molecular Probes, Carlsbad, CA, USA) for 10 min-
utes before mounting in Mowoil.
Staining was visualised on a laser scanning confocal micro-
scope (BioRad Radiance 2000; BioRad, Hemel Hempsted,
UK) and Z-series were merged using Lasersharp (BioRad)
software.http://genomebiology.com/2008/9/6/R101 Genome Biology 2008,     Volume 9, Issue 6, Article R101       Wishart et al. R101.19
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Data analysis
All non-SuperArray data were collected in Microsoft Excel
and all statistical analyses and graphs were produced using
GraphPad Prism. Quantification of cytoplasmic and nuclear
Ube1/TOPRO3 fluorescence was undertaken on confocal
micrographs captured using identical microscope settings
between images and specimens. No image manipulation was
undertaken before quantification using standard fluores-
cence intensity tools in Image J software. Images were pre-
pared for presentation in Adobe Photoshop.
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